Dr. Reddy's Laboratories Limited (DRREDDY)
Valuation Rating
Score: 27/100
Valuation Overview
| P/E Ratio | 18.00715 |
| P/B Ratio | 3.037534 |
| Dividend Yield | 69.0% |
| Current Price | ₹1158.4 |
| DCF Value | ₹407.85904280522425 |
| Upside Potential | N/A% |
Intrinsic Values
| Current Price | ₹1158.4 |
| DCF Value | ₹407.85904280522425 |
| Graham Value | ₹804.125 |
| DDM Value | ₹115.42857142857142 |
| Earnings Value | ₹155.8501059025911 |
| Average Value | ₹389.67710617200004 |
Growth Confidence
| Revenue Growth | 0% |
| Earnings Growth | 0% |
| Revenue Confidence | 0% |
| Earnings Confidence | 0% |
| Margin Confidence | 0% |
| Overall Growth Confidence | 0% |
Growth Metrics
| EPS Growth | 2.4% |
| Revenue Growth | 15.9% |
| Market Cap | ₹96587.63 Cr |
Valuation Analysis Score: 27/100
Undervaluation Score: 27/100
Valuation Score: 17/30
Growth Score: 10/30
Intrinsic Value Score: 0/40
Growth Score: 10/30
Intrinsic Value Score: 0/40
Key Analysis Points:
- Good P/E ratio below 20
- Excellent operating margins above 20%
- High growth confidence score above 80%
Recommendation
Caution - Stock may be overvalued, detailed analysis recommended
Detailed Metrics
Current Price: ₹1,158.40
Operating Margins: 22.4%
Revenue Growth: 0.0%
Earnings Growth: 0.0%
Growth Confidence: 86.2%
Risk Assessment Guide
- Score 80-100: Significantly undervalued with strong fundamentals
- Score 60-79: Moderately undervalued with good potential
- Score 40-59: Fairly valued with balanced metrics
- Score Below 40: Potentially overvalued, exercise caution
Last Updated: 2025-04-16 19:12:44